DD-3 is a drug discovery program focused on the identification of new molecules for innovative treatments of inflammatory diseases such as osteoarthritis. The project is the result of a partnership agreement between three pharmaceutical companies: Almirall, Esteve and Palau, and one biotechnological company: Proteomika.

The main goals of the Neogenius Pharma project are: to identify novel compounds through novel mechanisms of action that offer a competitive advantage over the current treatments, and to identify specific biomarkers that offer a better understanding of the patients suffering from such inflammatory diseases.

DD-3 is partially funded by CDTI , supported by Ministerio de Ciencia e Innovación, Fondo de Inversión Local para el Empleo - Gobierno de España.